1- (2- chloroethyl)- 3- (2- (dimethylaminosulfonyl)ethyl)- 1- nitrosourea (tauromustine)

08/01/1988 - "These data suggest that TCNU may be useful in the management of large bowel cancer as the MAC system has been previously shown to be a good model of human disease."
01/01/1991 - "Compared to control animals, TCNU decreased tumor growth. "
05/01/1990 - "The variability in the tissue level of TCNU was partly attributable to variable absorption of the drug, since peak plasma TCNU levels ranged from 164 to 3333 ng/ml. There were close quantitative and temporal relationships between the times of peak plasma levels (median 456 ng/ml at 45 minutes after administration), peak tumor levels (median 250 ng/gm tissue at 55 minutes), and brain adjacent to tumor levels (median 256 ng/gm tissue at 50 minutes). "
05/01/1990 - "High-performance liquid chromatography analysis of 32 tumor specimens for TCNU revealed that tissue concentrations ranged from 0 to 554 ng/gm: TCNU was not detected in necrotic regions of the tumor. "
01/01/1989 - "Pharmacokinetics of tauromustine in cancer patients. "

07/01/1990 - "TCNU in adenocarcinoma of the lung: a phase II study with divided doses."
02/01/1994 - "The effect of administering divided dose schedules of TCNU was examined against the murine adenocarcinomas of the colon, MAC 13 and MAC 26, and the Lewis lung tumour and drug metabolism was examined in the different tumour bearing mouse strains. "
07/01/1990 - "Accordingly, 38 consecutive patients with non-resectable adenocarcinoma of the lung received TCNU 40 mg/m2 p.o. "
08/01/1988 - "TCNU is highly active against a panel of three histologically distinct transplantable murine adenocarcinomas of the colon (MAC tumours). "
08/01/1988 - "The novel nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosoure a (TCNU) is active against a panel of three transplantable murine adenocarcinomas of the colon of varying growth characteristics and morphology (MAC system). "

08/01/1988 - "Phase II study of TCNU in advanced breast cancer."
10/01/1987 - "Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study."
01/01/1987 - "TCNU produced significantly greater cytotoxicity in the Mer- cells (Walker 256 rat breast carcinoma resistant to nitrogen mustards; human lung carcinoma A427) than in the Mer+ cells (Walker 256 wild-type; human lung carcinoma A594). "

01/01/1987 - "TCNU produced significantly greater cytotoxicity in the Mer- cells (Walker 256 rat breast carcinoma resistant to nitrogen mustards; human lung carcinoma A427) than in the Mer+ cells (Walker 256 wild-type; human lung carcinoma A594). "
01/01/1987 - "The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines."
09/01/1991 - "The effect of intravenously injected tauromustine (TCNU) on tumor growth and body weight was studied in rats with subcutaneously implanted experimental carcinomas. "
04/01/1988 - "TCNU and its two metabolites were found to exhibit equal or better oral efficacy than that of BCNU, CCNU, MeCCNU or chorozotocin against L1210 leukemia, Walker mammary carcinoma, Lewis Lung, Harding Passey melanoma and colon carcinoma C26. "
05/01/1993 - "Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069."

07/01/1989 - "It is concluded that TCNU is a well tolerated compound with limited, but definite antitumor activity against colorectal cancer and that further studies in this disease could be of interest."
02/01/1996 - "TCNU in colorectal cancer. "
01/01/1993 - "In 25 patients with advanced colorectal carcinoma (13 M, 12 F, median age 51 yrs), four dose levels of TCNU (25, 30, 35 or 40 mg/m2) were investigated. "
07/01/1989 - "TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. "
01/01/1990 - "5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results."